NERVGEN PHARMA CORP (NGEN.CA) Stock Price & Overview
TSX-V:NGEN • CA64082X2032
Current stock price
The current stock price of NGEN.CA is 5.15 CAD. Today NGEN.CA is up by 3%. In the past month the price decreased by -10.28%. In the past year, price increased by 92.88%.
NGEN.CA Key Statistics
- Market Cap
- 414.781M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.38
- Dividend Yield
- N/A
NGEN.CA Stock Performance
NGEN.CA Stock Chart
NGEN.CA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to NGEN.CA. When comparing the yearly performance of all stocks, NGEN.CA is one of the better performing stocks in the market, outperforming 79.65% of all stocks.
NGEN.CA Earnings
On November 24, 2025 NGEN.CA reported an EPS of -0.06 and a revenue of 77.07K. The company beat EPS expectations (0.99% surprise).
NGEN.CA Forecast & Estimates
8 analysts have analysed NGEN.CA and the average price target is 7.75 CAD. This implies a price increase of 50.52% is expected in the next year compared to the current price of 5.15.
NGEN.CA Groups
Sector & Classification
NGEN.CA Financial Highlights
Over the last trailing twelve months NGEN.CA reported a non-GAAP Earnings per Share(EPS) of -0.38. The EPS increased by 2.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -197.42% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NGEN.CA Ownership
NGEN.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.23 | 2.772B | ||
| CRON | CRONOS GROUP INC | 39.18 | 1.338B | ||
| TLRY | TILRAY BRANDS INC | N/A | 1.066B | ||
| DHT-UN | DRI HEALTHCARE TRUST | 5.17 | 904.914M | ||
| GUD | KNIGHT THERAPEUTICS INC | 155.29 | 730.324M | ||
| DHT-U | DRI HEALTHCARE TRUST | 5.33 | 671.122M | ||
| WEED | CANOPY GROWTH CORP | N/A | 565.768M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 22.49 | 475.264M | ||
| TSND | TERRASCEND CORP | N/A | 349.699M | ||
| HITI | HIGH TIDE INC | 10.35 | 283.038M | ||
| ACB | AURORA CANNABIS INC | 59.28 | 271.641M | ||
| OGI | ORGANIGRAM GLOBAL INC | 28.16 | 261.773M | ||
| CRDL | CARDIOL THERAPEUTICS INC-A | N/A | 221.245M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About NGEN.CA
Company Profile
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Company Info
IPO: 2019-03-13
NERVGEN PHARMA CORP
Suite 1703 - 595 Burrard Street
Vancouver BRITISH COLUMBIA V7X 1J1 CA
CEO: Paul Brennan
Employees: 7
Phone: 16047225361
NERVGEN PHARMA CORP / NGEN.CA FAQ
What does NERVGEN PHARMA CORP do?
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
What is the stock price of NERVGEN PHARMA CORP today?
The current stock price of NGEN.CA is 5.15 CAD. The price increased by 3% in the last trading session.
Does NERVGEN PHARMA CORP pay dividends?
NGEN.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of NGEN stock?
NGEN.CA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Is NERVGEN PHARMA CORP (NGEN.CA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NGEN.CA.
What is the market capitalization of NGEN stock?
NERVGEN PHARMA CORP (NGEN.CA) has a market capitalization of 414.78M CAD. This makes NGEN.CA a Small Cap stock.